Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system

Abstract

Immunotherapy has changed the treatment landscape for multiple cancer types. In the recent decade, great progress has been made in immunotherapy, including immune checkpoint inhibitors, adoptive T-cell therapy, and cancer vaccines. ICIs work by reversing tumor-induced immunosuppression, resulting in robust activation of the immune system and lasting immune responses. Whereas, their clinical use faces several challenges, especially the low response rate in most patients. As an increasing number of studies have focused on membrane immune checkpoint protein trafficking and degradation, which interferes with response to immunotherapy, it is necessary to summarize the mechanism regulating those transmembrane domain proteins translocated into the cytoplasm and degraded via lysosome. In addition, other immune-related transmembrane domain proteins such as T-cell receptor and major histocompatibility are associated with neoantigen presentation. The endosomal-lysosomal system can also regulate TCR and neoantigen-MHC complexes on the membrane to affect the efficacy of adoptive T-cell therapy and cancer vaccines. In conclusion, we discuss the process of surface delivery, internalization, recycling, and degradation of immune checkpoint proteins, TCR, and neoantigen-MHC complexes on the endosomal-lysosomal system in biology for optimizing cancer immunotherapy.

Pathogenic role of different phenotypes of immune cells in airway allergic diseases: a study based on Mendelian randomization

“…During the activation process of T cells, the CD3-TCR complex must first bind to antigenic peptide fragments presented by MHC on the surface of other antigen-presenting cells, subsequently activating the proliferation and inhibitory functions of T cells. Once T cells are activated, to limit the intensity of T-cell activation, cells achieve the recycling and degradation of the CD-TCR complex through endosomal recycling ( 30 ). This self-regulatory process occurs in almost all T cells, including Tregs.…”

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity

“…Various membrane protein receptors on the cell surface can specifically bind to extracellular ligands . Several well-established drug delivery systems have been developed to hijack these membrane receptors to facilitate the transfer of drug conjugates into the cell by receptor-mediated endocytosis .…”

“…Various membrane protein receptors on the cell surface can specifically bind to extracellular ligands. 18 Several wellestablished drug delivery systems have been developed to hijack these membrane receptors to facilitate the transfer of drug conjugates into the cell by receptor-mediated endocytosis. 19 These strategies have been successfully applied in the development of pro-PROTACs and may simultaneously address on-target off-tumor toxicity and improve drug metabolism and pharmacokinetic (DMPK) properties of conventional PROTACs.…”

Engineering siRNA therapeutics: challenges and strategies

“…During membrane fusion, endosomes containing siRNA fuse with the plasma membrane, releasing the siRNA into the cytoplasm. This process involves the fusion of endosomal membranes with lysosomal membranes or the plasma membrane, requiring the participation of proteins such as Rab GTPases, SNAREs, and ESCRT [ 43 , 44 ]. In contrast, the membrane disruption mechanism destabilizes siRNA-loaded endosomes by forming pores in the endosomal membrane.…”